Welcome to our dedicated page for Anterix SEC filings (Ticker: ATEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anterix Inc. (NASDAQ: ATEX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings detail how Anterix describes its business as a provider of private 900 MHz licensed spectrum and advanced intelligent infrastructure solutions for utilities and other critical infrastructure sectors.
In its periodic reports, Anterix presents financial statements and notes that cover spectrum revenue, gains on exchange and sale of spectrum-related intangible assets, investments in spectrum clearing, deferred revenue, contingent liabilities, cash and cash equivalents, and other key balance sheet and income statement items. Investors can review these documents to understand the company’s spectrum assets, contracted proceeds from customers, and pipeline of prospective contract opportunities.
Current reports on Form 8-K for Anterix include disclosures about quarterly and annual financial results, leadership changes such as the appointment or resignation of executive officers, shareholder meeting outcomes, and changes in the company’s independent registered public accounting firm. These filings provide timely information about significant corporate events and governance matters.
On Stock Titan, Anterix filings are accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as revenue drivers, spectrum transactions, and notable risk factors. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q, and 8-K filings, as well as other relevant forms, appear promptly. Users can also review insider-related disclosures when they are filed, gaining additional context on executive and director activity related to ATEX.
Anterix Inc. reported a leadership change, announcing that Chief Operating Officer Ryan Gerbrandt will leave the company effective January 9, 2026. His departure is tied to an internal reorganization in which the Chief Operating Officer position is being eliminated.
Subject to his signing a release of claims in favor of the company, Gerbrandt will receive severance benefits applicable to a Legacy Tier 1 Executive under Anterix’s Executive Severance Plan, as previously described in its 2025 proxy statement. This event reflects a structural change in the executive team rather than a disclosed change in the company’s financial outlook.
Anterix Inc. (ATEX) Chief Legal Officer and Corporate Secretary Gena L. Ashe reported a stock sale in a Form 4 filing. On 11/18/2025, she sold 6,564 shares of Anterix common stock at a price of $21.07 per share. After this transaction, she beneficially owns 13,366 shares of Anterix common stock directly.
Anterix Inc. reported a sharp turnaround to profitability for the quarter ended September 30, 2025. Net income was $53.5 million versus a $12.8 million loss a year ago, driven primarily by a $59.6 million non‑monetary gain from exchanging narrowband spectrum for broadband licenses and an $11.5 million gain on spectrum sales. Spectrum revenue was $1.6 million, essentially flat year over year.
Total assets rose to $420.4 million, including $325.3 million of intangible assets tied to spectrum. Deferred revenue reached $130.4 million, reflecting customer prepayments to be recognized over time, and remaining performance obligations were $178.5 million. Cash and cash equivalents were $39.1 million, with operating cash outflow of $1.7 million in the first half as gains were largely non‑cash.
The company advanced commercial deliveries, including transfers to LCRA and Oncor, and continued spectrum clearing and license exchanges. Operating expenses declined on lower G&A and product development costs, partially offset by severance related to workforce reductions.
Anterix Inc. furnished an update on its business performance, covering financial results and a key operating metric. The company announced its second quarter fiscal 2026 financial results for the three and six months ended September 30, 2025, and made the full earnings release available as an exhibit.
Anterix also posted an update on its "Demonstrated Intent" key performance indicator on its investor website, with that update likewise attached as an exhibit. Both the earnings release and the KPI update are furnished, not filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
Anterix Inc. (ATEX) disclosed insider equity activity by its CFO. On 09/29/2025, the officer received 11,405 restricted stock units. The grant vests 1/3 on September 29, 2026, with the remainder vesting in two equal annual installments thereafter.
On 10/04/2025, 404 shares were withheld at $22.55 to satisfy tax obligations tied to a partial RSU vest and settlement. Following these transactions, the officer directly owned 18,029 common shares.
Anterix Inc. (ATEX)7,028 shares of common stock, which include Restricted Stock Units: 877 shares vesting on May 15, 2026; 672 shares vesting on July 12, 2026; and 3,925 shares vesting in three equal annual installments beginning October 4, 2025.
The filing also lists a stock option for 3,680 shares at an exercise price of $40, expiring on 04/03/2035, vesting in three equal annual installments beginning October 4, 2025.
Anterix Inc. (ATEX) reported an initial statement of beneficial ownership. A company officer filed Form 3 effective 09/17/2025, disclosing 34,578 shares of common stock held directly. The filer is identified as an Officer (Chief Marketing Officer) and Chief of Staff. The filing also notes Restricted Stock Units that will vest in three equal installments beginning on September 9, 2026.
Anterix Inc. disclosed that on
Lang Scott A., President, CEO and Director of Anterix Inc. (ATEX), reported a personal purchase of company stock. On 09/18/2025 he acquired 4,650 shares of Common Stock at $21.28 per share and after the transaction beneficially owned 4,650 shares directly. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on the same date.
Anterix, Inc. (ATEX) disclosed a Chief Financial Officer transition: Timothy A. Gray resigned as CFO effective September 19, 2025, and the Board appointed Elena Marquez as CFO effective September 22, 2025. Ms. Marquez, age 39, has served as Vice President of Finance and Controller since September 2021 and previously held senior finance roles at Clinical Genomics and Prudential Financial. In connection with her promotion, she will receive additional restricted stock units with an aggregate grant date fair value of $250,000 vesting in three equal annual installments and will be eligible to participate in the Company’s Executive Severance Plan. The Board designated her as the company’s principal financial officer and principal accounting officer for SEC purposes. The filing notes standard indemnification and states there are no related-party or Item 404 transactions to disclose.
FAQ
What is the current stock price of Anterix (ATEX)?
What is the market cap of Anterix (ATEX)?
